SLC5A2 and Insulin resistance: Numerous clinical trials have confirmed that SGLT2 inhibitors can effectively reduce body weight, which may be related to increases in fat utilization, reductions in adipose tissue mass and browning in white adipose tissue, further attenuating obesity-induced insulin resistance [78,79,80,81,82].